Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen

Filik, L; Karakayali, H; Moray, G; Dalgic, A; Emiroglu, REMZİ; Ozdemir, N; Colak, T; Gur, G; Yilmaz, U; Haberal, M

doi:10.1016/j.transproceed.2005.12.047

Lamivudine therapy in kidney allograft recipients who are seropositive for hepatitis B surface antigen

Filik L., Karakayali H., Moray G., Dalgic A., Emiroglu R., Ozdemir N., ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.38, sa.2, ss.496-498, 2006 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 38 Sayı: 2
Basım Tarihi: 2006
Doi Numarası: 10.1016/j.transproceed.2005.12.047
Dergi Adı: TRANSPLANTATION PROCEEDINGS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.496-498
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background. There are numerous recent reports on the use of lamivudine for hepatitis B virus (HBV) infection after renal transplantation. However, the optimal strategy (prophylactic, preemptive, or salvage approach) for starting lamivudine treatment in this patient group has not been determined. The aim of this study was to assess how the timing of lamivudine therapy affected the HBV serological status and the transaminase levels in renal allograft recipients with chronic HBV infection.